Articles tagged with Prostate Cancer
Abarelix depot-M successfully suppresses testosterone levels, achieving suppression by day 8 and maintaining it from day 29 through day 85. The studies validated PRAECIS' core technology and demonstrate a potentially new treatment option for prostate cancer.
A Phase III trial shows long-term hormone suppression can control recurrence and improve survival in prostate cancer patients. The treatment significantly reduces disease-free survival, local progression, and freedom from distant metastasis.
Researchers found two protein biomarkers, cIAP-1 and XIAP, that correlate with distant metastasis-free survival in prostate cancer patients. Elevated levels of these proteins were associated with a higher risk of relapse after radiation therapy.
A study of 31 prostate cancer patients found that quality of life returns to normal within a year following brachytherapy, with urinary symptoms disappearing. The treatment was compared to other options like removal of the prostate or standard radiation therapy, which carry higher risks of decreased sexual function and bowel problems.
A study of 50 patients at the Veterans Affairs Medical Center in Atlanta found that rectally administered lidocaine gel significantly reduced pain during transrectal prostate biopsy. Patients who received lidocaine rated their pain as moderate to severe, while those without anesthetic experienced more discomfort.
Researchers found a new class of drugs called selective apoptotic anti-neoplastic drugs (SAANDs) that can safely slow tumor growth in men with advanced prostate cancer. The study showed significant results with minimal side effects.
Researchers present promising treatments for renal cell carcinoma using 5-aminolevulinic acid fluorescence detection, as well as a vaginal mucosal vaccine for recurrent urinary tract infections. Additionally, studies investigate the long-term health-related quality of life impacts of different prostate cancer therapies.
The Montreal Prostate Cancer Model estimates high disease-specific survival rates following prostatectomy, with comparable results to SEER data. The model also forecasts significant economic burdens of prostate cancer in Canada, totaling $9.76 billion over a lifetime.
The Vanderbilt-Ingram Cancer Center will establish a new prostate cancer center with a $1.5 million grant from the Department of Defense. The center aims to investigate signals promoting and inhibiting cell growth in prostate cancer.
Researchers have identified five genes statistically linked to prostate cancer in about 500 men. The strongest candidate has the hallmarks of a gene that thwarts cell division, potentially playing a major role in causing prostate cancer when it fails to function.
A new review of data from a recent nationwide trial shows the free prostate specific antigen test (fPSA) is as accurate in detecting prostate cancer risk in African American men as it is in Caucasians. The study found that nearly 75% of unnecessary prostate biopsies can be spared for black men.
Researchers aim to recruit at least 100 African-American families with a history of prostate cancer to participate in the PROGRESS study. The study seeks to identify genes linked to inherited prostate cancer, which may help diagnose, treat, and prevent the disease.
The American Urological Association has released new policy guidelines for prostate-specific antigen (PSA) testing, recommending a biopsy to confirm diagnosis when PSA levels are high or abnormal digital rectal examinations are performed. The guidelines also emphasize the importance of individualized decision-making and periodic testin...
Researchers at UT Southwestern Medical Center found that higher PSA levels are associated with faster prostate growth, allowing doctors to predict and potentially slow growth through treatment. This study provides critical information for planning a treatment, emphasizing the importance of annual PSA tests for men over age 50.
A high fibre diet was found to lower PSA levels in men, suggesting a potential link between soluble fibre and reduced prostate cancer risk. The study also supported existing advice to eat more vegetable foods and less animal products in preventing prostate cancer.
A study published in Urology found that men with prostate cancer are more likely to remain continent and potent after surgery performed by highly experienced surgeons. The study's potency and continency rates were the highest ever reported, with up to 93% of patients reporting continency and 65% reporting potency.
A new study found that eating three servings of vegetables daily can cut a man's risk of prostate cancer nearly in half. Cruciferous vegetables like broccoli and cabbage have the strongest effect, decreasing risk by 41% when consumed regularly.
Researchers at Cold Spring Harbor Laboratory identified eight previously unknown genes associated with prostate cancer. The study's 'guilt-by-association' method used statistical analysis to link genes mimicking PSA activity to the disease.
Scientists at the University of Rochester Medical Center are exploring the use of genetic algorithms to treat prostate cancer by improving how radiation is delivered. The formulas have been developed by medical physicist Yan Yu, Ph.D., who heads a task force on the subject for the American Association of Physicists in Medicine.
Researchers at UroGenesys identify a novel cell-surface antigen called STEAP, expressed on prostate cancers but rarely in non-prostate tissues. The discovery suggests STEAP may be a promising target for new treatments and diagnostic tools to monitor prostate cancer progression.
Researchers at Memorial Sloan-Kettering Cancer Center challenge current understanding of prostate cancer treatment by showing that testosterone withdrawal triggers a dormant state in tumor cells, rather than causing widespread cell death. This study offers new hope for developing targeted therapies to combat recurrent prostate cancer.
A large study by the Fred Hutchinson Cancer Center found no association between vasectomy and increased prostate cancer risk. Additionally, dietary supplementation with vitamins C and E was linked to a lower risk of prostate cancer. Men who took zinc supplements also saw a significant reduction in risk.
Researchers at Johns Hopkins Medicine successfully used gene therapy to activate the human immune system against metastatic prostate cancer. The study, published in Cancer Research, showed that patients' B-cells produced antibodies and T-cells directly attacked tumor cells after vaccination.
Researchers at UNC-CH will investigate prostate cancer mechanisms, including the role of androgens, to develop a potential cure. The team aims to understand why black men develop prostate cancer twice as often as white men do.
Researchers have identified a genetic mutation associated with an increased risk of prostate cancer in African-American and Latino men, with a five times greater risk compared to those without the mutation. The mutation affects the enzyme steroid 5a-reductase, leading to increased production of dihydrotestosterone, a potent form of tes...
Scientists found that osteonectin, a bone protein, attracts prostate cancer cells and stimulates their invasion. This discovery has important implications for the treatment of prostate cancer and other bone-seeking cancers.
Researchers are focusing on two isoflavones in soy: genistein and daidzein. Preliminary evidence suggests that predominantly daidzein may be of greater cardiovascular benefit.
UI researchers found that restoring E-cadherin protein hinders prostate cancer spread and enhances cell adhesion. The study provides a potential new approach to target invasive prostate cancer.
New research suggests that PSA testing alone cannot fully explain the decline in prostate cancer deaths since the early 1990s. Instead, other factors such as changing treatment patterns and misclassification of cause of death may be contributing to the trend.
Researchers will discuss cellular interactions in prostate cancer, new gene discoveries, and techniques for measuring patient outcomes. The symposium also features presentations on experimental agents, immunotherapies, and alternative therapies for treating prostate cancer.
A USCF study reveals that an herbal therapy, PC-SPES, significantly reduces prostate-specific antigen (PSA) levels by more than 50% in men with advanced prostate cancer. The compound, containing eight Chinese herbs including saw palmetto, showed promising results in both hormone-naïve and hormone-resistant patients.
Researchers at Thomas Jefferson University have found that radiation therapy helps patients with localized prostate cancer live longer. After examining the results of 1560 patients who received radiation therapy alone for prostate cancer, they discovered that those with high-risk disease benefited the most from higher doses of radiation.
A new study developed a simple method to assess the risk of deadly metastatic cancer in men after prostate removal. The chart uses three common measures, including Gleason score and PSA doubling time, to pinpoint the risk for developing metastatic cancer.
Research at Ohio State University found that a low-calorie diet slowed tumor growth in rats and mice with prostate cancer. The study suggested that maintaining proper energy balance may inhibit prostate cancer progression.
Researchers at the Fred Hutchinson Cancer Research Center and the University of Washington have mapped a gene associated with prostate cancer that runs in families, also linked to primary brain cancer. The study results appear in the American Journal of Human Genetics.
A national pilot study is testing whether soy supplementation can reduce prostate cancer risk in African-American men. The $494,588 study, led by Electra D. Paskett, Ph.D., will evaluate the effect of soy on markers for prostate cancer risk and assess its impact on cardiovascular health and quality of life.
A diet rich in phytosterols reduces testosterone levels and activity of enzymes that metabolize testosterone into more active forms. The study suggests a potential link between plant-based fats and lower rates of hormone-dependent cancers.
The Prostate Cancer Center of Excellence will focus on improving patient outcomes and offer hope to the more than 10,000 men in North Carolina diagnosed with the disease. The $5 million grant will fund new positions, labs, and studies addressing prevention and treatment aspects.
A study conducted by University of California San Francisco expert Mac Roach found that high-risk prostate cancer patients who receive hormonal therapy in conjunction with radiotherapy have a 20% higher survival rate after eight years compared to those receiving radiotherapy alone. This suggests that prostate cancer patients may need t...
A team of international researchers has pinpointed the site of the first gene for prostate cancer located on the human X chromosome. This discovery may account for almost 20 percent of disease in families with a strong history of the cancer.
A study found that high-risk prostate cancer patients treated with seed implant therapy had poorer outcomes compared to radical prostectomy and external beam radiation. The researchers suggest that high-risk patients should discuss alternative treatment options with their physicians.
DHEA supplements, believed to have anti-aging properties, may stimulate the production of IGF-1, increasing prostate cancer risk. Dr. Goldberg recommends monitoring serum DHEA, PSA, and IGF-1 levels for men taking DHEA supplements.
Researchers identified two distinct forms of prostate cancer, with one being more aggressive. The study also found that p27 plays a role in Benign Prostate Hyperplasia (BPH), which is genetically different from prostate cancer and not a precursor to its development.
A Northwestern University Medical School study found that low literacy levels were a significant predictor of having incurable prostate cancer among low-income white and black men. Poor reading skills were more prevalent among black men with advanced cancers, suggesting low literacy as a key factor in the disparity.
Researchers at the University of Pennsylvania Cancer Center have identified a genetic mutation in the CYP3A4 gene associated with prostate cancer progression. Men carrying this mutation are nearly 10 times more likely to develop advanced tumors, highlighting the potential for targeted prevention strategies.
The new technology enables doctors to assess pubic arch interference in minutes, allowing for better treatment decisions. It also reduces the need for expensive CT scans, which can cost up to $500 and take a week or more to obtain results.
A new study by USC/Norris Cancer Center scientists raises questions about the potential use of finasteride to prevent prostate cancer. Finasteride, commonly used to treat benign prostate disease, may not be effective as a chemopreventive agent against prostate cancer in men with high PSA levels.
A new molecule, Bin1, has been identified by Wistar scientists as a potential indicator of malignant prostate cancer. Bin1 interacts with and limits the malignant potential of Myc, a protein found frequently in prostate cancers.
Researchers found that anti-androgen drugs can trigger the protein that makes prostate and cancerous cells grow, leading to a possible explanation for why hormone therapy loses effectiveness after one or two years. The study suggests that more research is needed to confirm the results.
A new study by Johns Hopkins researchers found that older men have more extensive prostate disease even if their PSA levels are the same as younger men. The study suggests that age should be an additional guide in deciding whether to do further testing for non-palpable prostate cancer.
A new test measuring free PSA can accurately identify men at risk of prostate cancer, allowing for targeted biopsies and reducing unnecessary procedures. The test aims to cut the cost of prostate screening dramatically while sparing men from potential complications like infection and bleeding.
A new version of the PSA test detects 95% of prostate cancers and helps distinguish between cancer and benign conditions. The study reduces unnecessary biopsies and provides personalized risk assessments for men with borderline results.
Scientists at Duke University discovered a genetic switch that governs prostate cancer progression. The switch controls the production of FGF-R2 receptors, which can lead to
The FDA panel unanimously approved a new test for detecting prostate cancer, which catches almost all cancers and reduces unnecessary biopsies. The free PSA test, measuring unbound PSA in the blood, identifies patients who could benefit from surgery or treatments, reducing cancer-free men's biopsies by 20%.
Researchers found that high 'free' testosterone levels in adulthood and a small shoulder span may be related to hormone levels at various stages of development, suggesting a link between these factors and prostate cancer risk. Further study is needed to confirm these findings.
A new study of over 1,000 prostate cancer patients found that those who underwent surgery had remarkably good outcomes, with few reporting dissatisfaction or problems with urinary or sexual function. Despite fears about complications, most men felt healthier and satisfied with their treatment after surgery.
A new study by Washington University School of Medicine researchers found that a surprising 22 percent of men with prostate cancer had PSA levels between 2.6 and 4, highlighting the need for yearly PSA tests for men over 50. The study suggests that doctors may be missing cancers in this range due to outdated guidelines.
A new study by Johns Hopkins Medicine recommends reducing the annual frequency of prostate-specific antigen (PSA) testing for men between 50 and 70 years old, as most don't need frequent tests to detect curable cancers. The guidelines suggest PSA testing every two years is sufficient to identify most men with curable prostate cancer.
The newly revised nomograms combine clinical stage, Gleason score, and PSA level information to identify men who can be cured by surgery alone. The use of these nomograms should improve our ability to predict surgical curability and help patients make informed treatment decisions.
Researchers at the University of Pittsburgh Cancer Institute have found that vitamin D significantly reduces prostate cancer growth in rats. Tumors in treated rats were 88% smaller than those in control rats, and lung metastases were also reduced.